Ivermectin Medical Valley

Ivermectin, the active ingredient in Ivermectin Medical Valley, is an anthelmintic (macrocyclic lactone) presented as an oral formulation for oral use. It is employed to treat a range of parasitic infections in humans, including river blindness, strongyloidiasis, lymphatic filariasis, scabies and other intestinal helminths.

GNH USA supplies Ivermectin Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an antiparasitic agent that targets a variety of helminth and ectoparasite infections.

- Onchocerciasis: reduces microfilarial load and helps prevent blindness. - Strongyloidiasis: eliminates intestinal larvae and prevents systemic dissemination. - Lymphatic filariasis: decreases adult worm burden and reduces disease transmission. - Scabies: eradicates Sarcoptes scabiei mites and relieves itching. - Other intestinal helminth infections: clears nematode infestations such as ascariasis and hookworm.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Pruritus: itching at the site of parasite death. - Headache: mild tension‑type headache. - Abdominal pain: cramping or discomfort. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurologic effects: seizures, ataxia, or altered consciousness. - Anaphylaxis: acute allergic reaction with airway compromise. - Visual disturbances: blurred vision or optic neuritis. - Cardiac arrhythmias: rare conduction abnormalities.

Before prescribing Ivermectin, clinicians should consider several safety aspects.

- Pregnancy: use only if the potential benefit outweighs the risk; data are limited. - Liver disease: dose adjustment may be required in patients with hepatic impairment. - Age: pediatric dosing should follow weight‑based guidelines. - Renal impairment: monitor renal function in severe cases. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Ivermectin may interact with other medicines, necessitating careful review.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Other antiparasitics (e.g., albendazole): monitor for additive toxicity. - CNS depressants (e.g., benzodiazepines): observe for enhanced sedation. - Immunosuppressants (e.g., tacrolimus): watch for altered drug levels.